Clinical Trials Using Gedatolisib
Clinical trials are research studies that involve people. The clinical trials on this list are studying Gedatolisib. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib / Letrozole Or Palbociclib / Fulvestrant In Women With Metastatic Breast Cancer
This is a multicenter, open label, Phase 1b study in patients with mBC. This study will have a dose escalation to identify the maximum tolerated dose (MTD) of the combination of gedatolisib plus palbociclib / fulvestrant and gedatolisib plus palbociclib / letrozole and expansion to estimate the objective response rate (OR) of the combination of gedatolisib plus palbociclib / letrozole or palbociclib / fulvestrant.
Location: 6 locations
Palbociclib and Gedatolisib in Treating Patients with Advanced Solid Tumors or Lung, Pancreatic, or Head and Neck Cancer
This phase I trial studies the side effects and best dose of palbociclib and gedatolisib and how well they work in treating patients with solid tumors or lung, pancreatic, or head and neck cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment. Palbociclib and gedatolisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Location: 4 locations
Talazoparib and Gedatolisib in Treating Patients with Advanced Triple Negative or BRCA1 / 2 Positive, HER2 Negative Breast Cancer
This phase I / II trial studies the best dose of talazoparib when given together with gedatolisib and to see how well they work in treating patients with triple negative or BRCA1 / 2 positive, HER2 negative breast cancer that has spread to other places in the body and cannot be removed by surgery. Talazoparib and gedatolisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Talazoparib blocks an enzyme called PARP. Talazoparib causes cancer cells to die by breaking the tumor DNA and then stopping the tumor from repairing the damaged DNA. Gedatolisib blocks two receptors called PI3K and mTOR. By blocking these pathways, gedatolisib may cause cancer cells to die and stop growing.
Location: 4 locations
Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer (“GLACIER”)
This phase I / II trial studies the side effects of hydroxychloroquine with or without gedatolisib and to see how well they work in preventing cancer from coming back in patients with stage I-III breast cancer. Drugs used in chemotherapy, such as hydroxychloroquine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Gedatolisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving hydroxychloroquine alone or in combination with gedatolisib may reduce or eliminate breast cancer cells that have spread to the bone marrow in patients with stage I-III breast cancer.
Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania
Gedatolisib and Antibody-drug Conjugate PF-06647020 in Treating Patients with Metastatic Triple Negative Breast Cancer
This phase I trial studies the side effects of gedatolisib and antibody-drug conjugate PF-06647020 and how well they work in treating patients with triple negative breast cancer that has spread to other places in the body. Gedatolisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as antibody-drug conjugate PF-06647020, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving gedatolisib and antibody-drug conjugate PF-06647020 may work better than gedatolisib alone in treating patients with triple negative breast cancer.
Location: Indiana University / Melvin and Bren Simon Cancer Center, Indianapolis, Indiana
A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
This study will evaluate PF-05212384 (gedatolisib) PI3K / mTOR inhibitor)) in combination with either docetaxel, cisplatin or dacomitinib in select advanced solid tumors. The study will assess the safety, pharmacokinetics and pharmacodynamics of these combinations in patients with advanced cancer in order to determine the maximum tolerated dose in each combination. The cisplatin combination expansion portion will evaluate the anti tumor activity of PF 05212384 plus cisplatin in patients with TNBC in 2 separate Arms (Arm 1 and Arm 2).
Location: See Clinical Trials.gov